Zymofix and the EIC Accelerator: Microbes Grown on Farm Waste
Zymofix, a Belgian company founded as N-Fix, grows beneficial microorganisms for farming, such as strains that help plants take up nutrients or resist stress, on low-value agricultural residues using solid-state fermentation, which it says is cheaper than the liquid fermentation normally used for such products. It was selected in the EIC Accelerator's June 2023 cut-off and received an EU grant of €2.50 million for N-Spire, "Novel and Scalable microbial products for REgenerative agriculture", a €4.39 million project that ran from February 2024 to January 2026, according to CORDIS. The aim was a manufacturing platform for affordable, stable microbial biostimulants for row crops.
The latest report, to May 2025, says the pilot-scale fermentation units were fully operational, the integrated process was proven at pilot scale with a microbe count above 10⁹ per gram and purity above 98%, the products kept longer in storage than commercial references, and 14 field trials were running in five countries, according to the CORDIS reporting page. It also records early agreements with an agricultural cooperative and international agrochemical distributors. On 30 September 2026 Zymofix announced a Series A led by First Imagine! and a €6 million manufacturing plant in Deinze, according to Zymofix.
Company file
- Legal entity
- Zymofix, formerly N-Fix NV, Belgium
- Platform
- Zyft solid-state fermentation
- Investors
- First Imagine!, VP Capital, HTGF, The Nest Family Office
- Partners named
- Bayer Crop Science, Ghent University
- Incubator
- biotope
- Applications
- Biostimulants, biocontrol, biomining
- EIC funding
- Grant first
Where Zymofix Stands Now
Zymofix says customer demand now exceeds its capacity. The Deinze plant is to produce 300 tonnes a year from the fourth quarter of 2027, enough to treat about one million hectares, and a further €25 million expansion to 2,000 tonnes is planned for 2028. In April 2026 it completed a feasibility study with Bayer's biologics team showing that its process "can produce commercial strains that meet the quality benchmarks of established liquid fermentation processes", according to Zymofix. In June 2026 it won €1.9 million from the Flemish agency VLAIO for research with Ghent University. The size of the Series A was not disclosed.
The record
From N-Fix to Zymofix and a planned factory
The EIC project validated Zymofix's fermentation platform at pilot scale. In September 2026 the company announced a Series A and a €6 million plant in Deinze, due to produce from late 2027.
- Jun 2023EIC Accelerator cut-offN-Spiregrant first
- Feb 2024Project starts€2.50M EU grant
- Nov 2024Renamed Zymofix€2M round led by HTGF
- Jan 2026Project endsPilot SSF validated, 14 field trials
- Mar 2026200-litre fermenterExpands in-house capacity
- Apr 2026Bayer feasibility studyCommercial strains meet benchmarks
- Jun 2026VLAIO grant€1.9M, with Ghent University
- Sep 2026Series A and Deinze plant€6M site, 300 t a year
CORDIS, biotope and Zymofix.
"The integrated manufacturing process (pretreatment and SSF) has been proved at pilot scale."
Zymofix, report to the EICThe Technology: Solid-State Fermentation
Most microbial products are grown in large stainless-steel tanks of liquid nutrients, which is expensive, and the resulting products often have a short shelf life. Solid-state fermentation grows the microbes directly on moist solid material, here farm residues, which Zymofix says lowers cost and yields tougher organisms. The EU wants farmers to use fewer chemical fertilisers and pesticides, and cheaper biological products would make that easier for large crops like wheat and maize.
The plan
Planned production capacity
Zymofix plans a first line of 300 tonnes a year from late 2027 and, subject to its success, a €25 million expansion to 2,000 tonnes a year.
Zymofix, September 2026. Tonnes of product per year.
What the EIC Award Promised, and What the Record Shows
The award promised a scalable manufacturing platform and products validated in trials. The platform was proven at pilot scale, shelf life improved, and field trials ran across five countries. Commercial agreements were at an early stage when the project closed, and the regulatory focus shifted to biostimulants because biocontrol approval in Europe is slower. The factory announcement and Bayer study show the platform is moving to industrial use.
- Pilot manufacturingDeliveredProven at pilot scale.
- Shelf lifeDeliveredBetter than references.
- Field validationIn progress14 trials, 5 countries.
- Industrial scaleCommittedPlant announced, 2026.
The Money
The EU paid 57% of the project. Zymofix raised €2 million in 2024 in a round led by High-Tech Gründerfonds, according to biotope, and a Series A of undisclosed size in 2026. It says the first plant will be financed partly by the equity round and partly by revenue from existing customer programmes.
The money
Disclosed funding and investment plans
The amount of the September 2026 Series A was not disclosed. The first plant costs €6 million; the planned expansion €25 million.
Zymofix, biotope and CORDIS. Values in € millions.
The project budget
Who paid for the €4.39M project
The EU covered 57% of the N-Spire project's cost.
CORDIS, project 101144502. Values in € millions.
What Cannot Be Checked
Questions for the EIC
What the field trials showed on crop yields, how large the Series A was, who Zymofix's paying customers are, and what its revenue is are not public.
Why Europe Should Care
Europe's farm-to-fork goals rely on biological alternatives to chemicals, and the cost of making microbes has held them back. Turning crop residues into microbial products is also a circular use of waste. Zymofix has moved from pilot to factory planning with EIC support.
What the award promised
A scalable platform to make affordable microbial farm products from biomass residues.
What the record shows
A platform the company says is pilot-proven, field trials, a Bayer feasibility study and a planned factory.
The Verdict
Delivered and scaling
Zymofix says it delivered the pilot platform the EIC funded and is now building industrial capacity. Its commercial results will show from 2027.
Zymofix and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.
Industry
AgrifoodCrop inputs
- Focus
- Biostimulants
- Technologies
- Microbial fermentation
- Keywords
- Solid-state fermentation
- Beneficial microbes
- Agricultural residues
- Biological control